Vontobel Holding
RXRX icon

Vontobel Holding’s Recursion Pharmaceuticals RXRX Stock Holding History

Vontobel Holding’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.6K Buy
11,600
+200
+2% +$773 ﹤0.01% 1179
2025
Q4 		$46.6K Hold
11,400
– – ﹤0.01% 1407
2025
Q3 		$55.6K Sell
11,400
-400
-3% -$2.1K ﹤0.01% 1320
2025
Q2 		$59.7K Hold
11,800
– – ﹤0.01% 1224
2025
Q1 		$62.4K Buy
11,800
+1,200
+11% +$8.75K ﹤0.01% 1057
2024
Q4 		$71.7K Hold
10,600
– – ﹤0.01% 1055
2024
Q3 		$69.9K Buy
+10,600
New +$76K ﹤0.01% 1048

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vontobel Holding's RXRX Position: Q1 2026 in Review

Vontobel Holding increased its Recursion Pharmaceuticals (RXRX) stake by 1.8% in Q1 2026, buying an estimated $773 and bringing the position to 11,600 shares worth $35.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

Vontobel Holding first reported a position in RXRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $71.7K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Vontobel Holding held 11,600 shares of Recursion Pharmaceuticals worth $35.6K as of Q1 2026.
  • Vontobel Holding bought 200 Recursion Pharmaceuticals shares in Q1 2026, an estimated $773.
  • Recursion Pharmaceuticals made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #1179 holding.
  • Vontobel Holding first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Vontobel Holding's Recursion Pharmaceuticals position peaked at $71.7K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.